RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-04-30
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+17.8%
Last 4 quarters
Revenue YoY growth
+5.5%
Most recent quarter
EPS YoY growth
+77.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.7%
Last 1 reports
Positive reaction rate
100%
1 of 1 quarters
Largest single-day move
+0.7%
2024-11-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2024-11-04 | $-0.37 | +2.6% | $5.80 | $5.84 | +0.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2024-09-30 | $-0.38 | $-0.37 | +2.6% | $59.88M | +5.5% |
| 2024-06-30 | $-0.53 | $-0.36 | +32.1% | $65.39M | +12.5% |
| 2024-03-31 | $-0.75 | $-0.58 | +22.7% | $51.94M | +5.3% |
| 2023-12-31 | $-0.72 | $-0.62 | +13.9% | $69.80M | +39.8% |
| 2023-09-30 | $-0.85 | $-1.63 | -91.8% | $56.78M | +95.7% |
| 2023-06-30 | $-0.78 | $-0.80 | -2.6% | $58.13M | +104.9% |
| 2023-03-31 | $-0.70 | $-0.74 | -5.7% | $49.33M | +95.3% |
| 2022-12-31 | $-0.95 | $-0.95 | +0.0% | $49.92M | +92.4% |
| 2022-09-30 | $-0.89 | $-1.17 | -31.5% | $29.02M | — |
| 2022-06-30 | $-0.86 | $-0.88 | -2.3% | $28.37M | — |
| 2022-03-31 | $-0.83 | $-0.94 | -13.3% | $25.26M | — |
| 2021-12-31 | $-1.00 | $-0.93 | +7.0% | $25.95M | — |
Frequently asked questions
Has Revance Therapeutics, Inc. beaten earnings estimates?
Revance Therapeutics, Inc. has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +17.8% over the last 4 quarters.
How does RVNC stock react to earnings?
RVNC stock has moved an average of +0.7% in the trading day following earnings over its last 1 reports, with positive reactions in 100% of those quarters.
What is Revance Therapeutics, Inc.'s revenue growth rate?
Revance Therapeutics, Inc. reported year-over-year revenue growth of +5.5% in its most recent quarter, with EPS growing +77.3% year-over-year.